TICKERNERD
Menu
AMIXAMIXHealthcare · Medical Devices

AMIX Stock Forecast: Autonomix Medical, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$4.37

The 2 Wall Street analysts covering Autonomix Medical, Inc. hold a median 12-month price target of $59 — +1245.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.2M
Ticker Nerd rank
11 / 100
Median analyst target
$59
Analysts covering
2
Revenue$0.0
Operating income−$2.8M
Net income−$2.7M
Free cash flow−$3.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

AMIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Autonomix Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
11 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
94
Accruals
57
Momentum
31
Growth
28
Issuance
25
Revisions
25
Value
6
Volatility
5
Quality
5

Size (94): Smaller than most of the companies we track.

Quality (5): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AMIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMIX, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $42Median $59High $76

The green dot is the last close — the median target sits +1245.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Feb 2026Maxim GroupMaintainsBuy$5.00 → $2.00
29 Apr 2025Maxim GroupInitiatesBuy—
3 Sept 2024Ladenburg ThalmannInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMIX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AMIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Autonomix Medical, Inc. (AMIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.1×

Cheaper than 77% of US stocks

Price / sales
—
Price / book
0.7×

Cheaper than 80% of US stocks

EV / EBITDA
−0.0×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−316.0%

Higher than 5% of US stocks

Return on assets
−157.8%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Autonomix Medical, Inc. (AMIX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Autonomix Medical, Inc. has a market value of $4.2M and an enterprise value of $783K.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$16.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$13.2M.

  • Shares outstanding: 543,000.

  • Trailing P/E: −0.1×; forward P/E: −0.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Autonomix Medical, Inc. employs 8 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Sept 2026

Data provided by Twelve Data

Peers

AMIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
AMIXAutonomix Medical, Inc.$4.2M
11
CODXCo-Diagnostics, Inc.$7.8M
37
WOKWORK Medical Technology Group Ltd.$8.4M
16
ICCMIceCure Medical Ltd.$7.6M
38
NVNOenVVeno Medical Corp.$7.3M
32
AIDX20/20 Biolabs, Inc.$6.9M
3
INBSIntelligent Bio Solutions, Inc.$6.4M
11

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Autonomix Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMIX news & analysis

Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026

GlobeNewsWire · 1 Sept 2026positive

Autonomix Medical announced that two scientific abstracts have been accepted for poster presentation at the CIRSE 2026 Annual Congress, taking place September 5-9, 2026, in Copenhagen, Denmark. The abstracts highlight the potential of Autonomix's transvascular technology in pain management and nervous system mapping.

Why it matters — The acceptance of the abstracts for a major European radiological congress provides third-party validation and increased visibility for Autonomix's transvascular technology across pain management and nervous system mapping.

Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery

GlobeNewsWire · 26 Aug 2026positive

Autonomix Medical announced the expansion of its intellectual property portfolio with a new U.S. patent covering feedback-guided precision neuromodulation and targeted therapy delivery. The patent broadens protection around systems that integrate real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain.

Why it matters — A stronger IP portfolio helps protect Autonomix's neuromodulation and targeted therapy technologies, which could be central to its competitive positioning in the cancer pain treatment space.

Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules

GlobeNewsWire · 25 Aug 2026neutral

Autonomix Medical announced it entered into a warrant inducement agreement with an investor for the immediate exercise of its outstanding July 2026 Warrants, covering 857,462 shares at an exercise price of $5.75. Gross proceeds from the exercise are expected to total approximately $4.9 million, before financial advisory fees and offering expenses.

Why it matters — AMIX watchers would care because the warrant exercise is expected to bring in roughly $4.9 million in gross proceeds for the Company.

Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission

GlobeNewsWire · 12 Aug 2026positive

Autonomix Medical announced the successful completion of its Good Laboratory Practice (GLP) preclinical study, which was conducted per FDA standards and evaluated the safety, functionality, and performance of its platform across multiple anatomical targets in porcine models. Final histology and laboratory analyses supported the study's safety and performance objectives, marking a key regulatory step toward the company's FDA submission.

Why it matters — AMIX watchers would care because completing the GLP preclinical study brings the company one step closer to its FDA submission, a key regulatory milestone for advancing its precision nerve-targeted treatment platform.

Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award

GlobeNewsWire · 10 Aug 2026positive

Autonomix Medical congratulated its co-founder and Chief Medical Officer, Dr. Robert Schwartz, on receiving the 2026 Cardiovascular Tech Forum Lifetime Achievement Award. The recognition honours him as one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care.

Why it matters — The award highlights the prestige and industry recognition of one of Autonomix's key leaders, reflecting positively on the company's executive standing in medical technology.

FAQ

Frequently asked questions about AMIX stock

What is the AMIX stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Autonomix Medical, Inc. have a median 12-month price target of $59, with estimates ranging from $42 to $76. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMIX stock a buy right now?

Of the 2 analysts covering Autonomix Medical, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Autonomix Medical, Inc. 11 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMIX?

As at 12 Sept 2026, Autonomix Medical, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).

Will AMIX stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +1245.5% from the last close, and Ticker Nerd's factor model ranks Autonomix Medical, Inc. 11 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMIX stock forecast for 2030?

No analyst covering Autonomix Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $42 to $76 over the next 12 months.

What does Autonomix Medical, Inc. do?

Autonomix Medical Inc. is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system.

What is the latest news on AMIX?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026". Autonomix Medical announced that two scientific abstracts have been accepted for poster presentation at the CIRSE 2026 Annual Congress, taking place September 5-9, 2026, in Copenhagen, Denmark. The abstracts highlight the potential of Autonomix's transvascular technology in pain management and nervous system mapping.

Company

About Autonomix Medical, Inc.

Autonomix Medical Inc. is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its current platform centers on a catheter-based, microchip-enabled sensing array designed to detect and differentiate neural signals with high sensitivity from within the vascular system. The company is developing this technology for applications in pancreatic cancer and pancreatitis, while also addressing areas such as chronic pain management, hypertension, cardiovascular conditions, and other nerve-related disorders. Autonomix Medical Inc. operates as a single-segment business dedicated to improving how neural conditions are diagnosed and treated through minimally invasive, signal-detection-based tools. Headquartered in The Woodlands, Texas, Autonomix Medical Inc. serves the medical technology market with a specialized focus on nerve-targeted interventions and disease management.

CEO Mr. Bradley Hauser · 8 employees · United States · https://autonomix.com